These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 35413402)
41. Tailoring supersaturation from amorphous solid dispersions. Li N; Taylor LS J Control Release; 2018 Jun; 279():114-125. PubMed ID: 29654798 [TBL] [Abstract][Full Text] [Related]
42. Amorphous Solid Dispersions Containing Residual Crystallinity: Competition Between Dissolution and Matrix Crystallization. Moseson DE; Corum ID; Lust A; Altman KJ; Hiew TN; Eren A; Nagy ZK; Taylor LS AAPS J; 2021 May; 23(4):69. PubMed ID: 34002256 [TBL] [Abstract][Full Text] [Related]
43. Poly (amino acid)s as new co-formers in amorphous solid dispersion. Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970 [TBL] [Abstract][Full Text] [Related]
44. Release Enhancement by Plasticizer Inclusion for Amorphous Solid Dispersions Containing High T Correa-Soto CE; Gao Y; Indulkar AS; Zhang GGZ; Taylor LS Pharm Res; 2023 Mar; 40(3):777-790. PubMed ID: 36859747 [TBL] [Abstract][Full Text] [Related]
45. Dissolution Behavior of Weakly Basic Pharmaceuticals from Amorphous Dispersions Stabilized by a Poly(dimethylaminoethyl Methacrylate) Copolymer. Frank DS; Prasad P; Iuzzolino L; Schenck L Mol Pharm; 2022 Sep; 19(9):3304-3313. PubMed ID: 35985017 [TBL] [Abstract][Full Text] [Related]
46. Simultaneous Water Sorption and Crystallization in ASDs 1: Stability Studies Lasting for Two Years. Grönniger B; Kimpe K; Singh A; Sadowski G Mol Pharm; 2024 Feb; 21(2):957-969. PubMed ID: 38173336 [TBL] [Abstract][Full Text] [Related]
47. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats. Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980 [TBL] [Abstract][Full Text] [Related]
48. Microstructure Formation for Improved Dissolution Performance of Lopinavir Amorphous Solid Dispersions. Li N; Taylor LS Mol Pharm; 2019 Apr; 16(4):1751-1765. PubMed ID: 30811205 [TBL] [Abstract][Full Text] [Related]
49. Physical stability and release properties of lumefantrine amorphous solid dispersion granules prepared by a simple solvent evaporation approach. Trasi NS; Bhujbal SV; Zemlyanov DY; Zhou QT; Taylor LS Int J Pharm X; 2020 Dec; 2():100052. PubMed ID: 32760909 [TBL] [Abstract][Full Text] [Related]
50. Combining amorphous solid dispersions for improved kinetic solubility of posaconazole simultaneously released from soluble PVP/VA64 and an insoluble ammonio methacrylate copolymer. Danda LJA; Batista LM; Melo VCS; Soares Sobrinho JL; Soares MFR Eur J Pharm Sci; 2019 May; 133():79-85. PubMed ID: 30890364 [TBL] [Abstract][Full Text] [Related]
51. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization. Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284 [TBL] [Abstract][Full Text] [Related]
52. Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability. Budiman A; Lailasari E; Nurani NV; Yunita EN; Anastasya G; Aulia RN; Lestari IN; Subra L; Aulifa DL Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631330 [TBL] [Abstract][Full Text] [Related]
53. Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature and Mechanisms of Impacts of Drugs on Each Other's Solution Concentrations. Arca HÇ; Mosquera-Giraldo LI; Dahal D; Taylor LS; Edgar KJ Mol Pharm; 2017 Nov; 14(11):3617-3627. PubMed ID: 28872867 [TBL] [Abstract][Full Text] [Related]
54. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder. Ghosh I; Snyder J; Vippagunta R; Alvine M; Vakil R; Tong WQ; Vippagunta S Int J Pharm; 2011 Oct; 419(1-2):12-9. PubMed ID: 21782911 [TBL] [Abstract][Full Text] [Related]
55. Reactive Melt Extrusion To Improve the Dissolution Performance and Physical Stability of Naproxen Amorphous Solid Dispersions. Liu X; Zhou L; Zhang F Mol Pharm; 2017 Mar; 14(3):658-673. PubMed ID: 28135108 [TBL] [Abstract][Full Text] [Related]
56. Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment. Caggiano NJ; Armstrong MS; Georgiou JS; Rawal A; Wilson BK; White CE; Priestley RD; Prud'homme RK Mol Pharm; 2023 Sep; 20(9):4546-4558. PubMed ID: 37578286 [TBL] [Abstract][Full Text] [Related]
57. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption. Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903 [TBL] [Abstract][Full Text] [Related]
58. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System. Baghel S; Cathcart H; O'Reilly NJ Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788 [TBL] [Abstract][Full Text] [Related]
59. Solubility advantage from amorphous etoricoxib solid dispersions. Dani P; Puri V; Bansal AK Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771 [TBL] [Abstract][Full Text] [Related]
60. Effects of Surfactants on Itraconazole-HPMCAS Solid Dispersion Prepared by Hot-Melt Extrusion I: Miscibility and Drug Release. Solanki NG; Lam K; Tahsin M; Gumaste SG; Shah AV; Serajuddin ATM J Pharm Sci; 2019 Apr; 108(4):1453-1465. PubMed ID: 30395834 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]